Introduction {#Sec1}
============

Obstructive sleep apnea hypopnea syndrome (OSAHS), the most frequent sleep-related breathing disorder, is characterized by repetitive events of partial or complete collapse of upper airway during sleep. Clinically, it is characterized by snoring, witnessed apneic episodes, marked sleep fragmentation and daytime sleepiness, which would lead to metabolic disturbance, impaired quality of life, high morbidity as well as high mortality \[[@CR1]\]. Approximately 10% of middle-aged men and 3% of middle-aged women are estimated to have moderate-severe OSAHS in the developed world \[[@CR2]\]. The pathogenesis responsible for the syndrome is not completely elucidated, but there exist multiple potential etiologies. One of the most important risk factors is obesity, especially visceral obesity \[[@CR3], [@CR4]\]. In obese population, the prevalence of OSAHS reaches up to 40--50% \[[@CR5]\]. In addition, OSAHS is associated with insulin resistance which can account for a further increase in metabolic syndrome especially of type 2 diabetes mellitus and cardio-cerebrovascular diseases \[[@CR6]\].

Adiponectin (Acrp30) is one of the common adipocytokines largely secreted by adipocytes and has insulin-sensitizing, anti-inflammatory and anti-atherosclerosis properties \[[@CR7]\]. Reduced levels of adiponectin are commonly observed in a variety of states associated with obesity and insulin resistance, such as type 2 diabetes mellitus. However, the relationship between OSAHS and serum/plasma adiponectin levels is complex and multidirectional. The complex relationship is due in part to the fact that obesity could be a cause, consequence, or confounding factor of OSAHS. In addition, some studies revealed that adiponectin levels in OSAHS patients were lower than that in non-OSAHS group \[[@CR8]--[@CR10]\]. While Wolk et al. found that higher adiponectin levels in OSAHS patients compared to controls \[[@CR11]\]. Tokuda et al. and Ursavas et al. revealed that there was no significant difference of adiponectin levels in OSAHS patients when compared to controls \[[@CR12], [@CR13]\].

Thus, we sought to perform a meta-analysis using all available relevant studies to assess the association between adiponectin levels and OSAHS. Given that most of the previous findings were confounded by obesity, sex and age, we only included studies that found no statistically significant difference between OSAHS patients and controls in terms of age, gender and body mass index (BMI) to address these possible confounding factors.

Methods {#Sec2}
=======

This meta-analysis is being reported in accordance with Preferred Reporting items for Systematic Reviews and Meta-analysis (PRISMA) statement \[[@CR14]\].

Search strategy {#Sec3}
---------------

We performed a comprehensive literature search to locate eligible articles published on electronic databases including PubMed, EMBASE, Cochrane Library, WANFANG (Chinese database), VIP (Chinese Database) and Chinese National Knowledge Infrastructure (CNKI). Keywords and search strategy were as follows: "obstructive sleep apnea hypopnea syndrome" or "OSAHS" or "obstructive sleep apnea" or "OSA" or "obstructive sleep apnea syndrome" or "OSAS" or "obstructive sleep hypopnea" or "sleep apnea" combined with "adiponectin" or "ADPN" or "APN". The electronic databases were searched from inception through January 2018. Besides, the references cited in these articles were reviewed to identify additional publications. We only recruited data from fully published articles written in English and Chinese.

Study selection {#Sec4}
---------------

Two reviewers first independently reviewed the titles and abstracts to identify relevant articles. A second screening was based on full-text articles to further see whether they were eligible for inclusion. Any disagreement was resolved by discussion.

Inclusion and exclusion criteria of literature {#Sec5}
----------------------------------------------

The studies that satisfied the following criteria were included:The study design was a case-control study that must have reported values in mean and standard deviation or median with range of adiponectin levels;The study must have included at least two separate groups with one being a groupconsisting of individuals with OSAHS and the other consisting of individuals without OSAHS;3)OSAHS was defined as apnea hypopnea index (AHI) ≥ 5;4)All OSAHS patients were diagnosed for the first time, without receiving any form of treatment;5)No statistically significant difference was found between OSAHS patients and controls in terms of age, gender and BMI;6)All participants were adults (age \> 18 years).

The exclusion criteria were:Conference abstracts, reviews articles and case reports;Original papers that did not contain precise data about serum/plasma levels of adiponectin in patients or controls;Studies were not performed in humans;Duplicate publication of articles.

Data extraction {#Sec6}
---------------

The following information was recorded from each included study: first author's name, publication year, population country, total simple size, serum/plasma adiponectin levels in patients or controls, age, gender, BMI and assay approaches for adiponectin levels.

Quality assessment {#Sec7}
------------------

The methodological quality of included studies was evaluated using the Newcastle-Ottawa scale (NOS) by two investigators independently. Discord was resolved by a third reviewer. The quality scale consists of three parts: selection, comparability and exposure assessment. The quality score ranges from 0 to 9. In our meta-analysis, we considered a study which is equal to or higher than 6 stars as a high-quality study.

Statistical analysis {#Sec8}
--------------------

Due to the inconsistency of measurement units and assay approaches, standardized mean difference (SMD) with 95% confidence intervals (CI) was chosen as effect size. Heterogeneity test was performed by Cochrane Q test and I^2^ test. Generally, if *P* \< 0.05 (Q-test) or I^2^ \> 50%, the heterogeneity was thought to exist and then the random-effect models would be used. Otherwise, fixed-effect models would be applied. An I^2^ of 25 to 49% was considered to represent a low level of heterogeneity, 50 to 74% a moderate level, and 75 to 100% a high level. Subgroup analysis was performed to assess the impact of race, adiponectin source, assay approaches, average age, BMI and AHI. Sensitivity analysis was conducted to evaluate the stability of pooled results. Potential publication bias was assessed by using the funnel plots, Begg's rank correlation method and the Egger's linear regression method. The statistical analysis was performed with Revman 5.3 and Stata12.0 software. *P* \< 0.05 were considered statistically significant.

Results {#Sec9}
=======

Search result {#Sec10}
-------------

A total of 397 relevant articles were preliminarily identified. After removing duplicates and screening by titles and abstracts, 312 articles were excluded. The remaining 85 articles were projected to be assessed according to the inclusion and exclusion criteria after reading the full-text. Then another 65 articles were excluded due to different reasons. Finally, a total of 20 studies with 28 datasets met inclusion criteria and were pooled for this meta-analysis \[[@CR8], [@CR10]--[@CR12], [@CR15]--[@CR30]\]. A flow diagram of the study selection process is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of screened and included papers

Characteristics of the eligible studies {#Sec11}
---------------------------------------

A total of 20 studies involving 1356 participants (OSAHS subjects \[*N* = 878\] and controls \[*N* = 478\]) were included in our meta-analysis. The information of the first author's name, publication year, population country, total simple size, assay approaches and NOS score of each study were showed in Table [1](#Tab1){ref-type="table"}. The information of adiponectin levels, age, BMI and AHI are given in Table [2](#Tab2){ref-type="table"}.Table 1Characteristics of included studiesAuthorYearCountryN (OG/CG)Adiponectin SourceAssay approachNOSHuang et al. \[[@CR26]\]2004China84 (69/15)SerumRIA6Zhang et al. \[[@CR8]\]2005China86 (66/20)SerumRIA6Wolk et al. \[[@CR11]\]2005USA55 (26/29)PlasmaRIA7Sharma et al. \[[@CR15]\]2007India80 (40/40)PlasmaELISA7Ursavas et al. \[[@CR12]\]2010Turkey70 (55/15)SerumRIA8Ebru et al. \[[@CR16]\]2011Turkey50 (26/24)SerumRIA7Öztürk et al. \[[@CR18]\]2012Turkey94 (62/32)SerumELISA6Sánchez et al. \[[@CR17]\]2012Spain41 (21/20)PlasmaRIA7Kritikou et al. \[[@CR19]\]2013USA67 (36/31)SerumELISA7Hargens et al. \[[@CR10]\]2013USA30 (12/18)SerumELISA8Mutairi et al. \[[@CR20]\]2014Kuwait147 (105/42)PlasmaELISA7Xu et al. \[[@CR28]\]2014China82 (62/20)SerumELISA7Wen et al. \[[@CR27]\]2015China48 (33/15)SerumELISA7Kim et al. \[[@CR22]\]2015Korea59 (37/22)PlasmaRIA7Araújo et al. \[[@CR21]\]2015Brazil53 (33/20)PlasmaELISA7Zuo et al. \[[@CR29]\]2016China89 (59/30)SerumELISA6Lacedonia et al. \[[@CR23]\]2016Italy20 (10/10)SerumELISA7Yang et al. \[[@CR30]\]2017China73 (35/38)SerumELISA7Abdel et al. \[[@CR24]\]2017Egypt44 (22/22)SerumELISA7Chen et al. \[[@CR25]\]2017China84 (69/15)SerumELISA8*OG* OSAHS group, *CG* control group, *N* sample size, *NOS* Newcastle-Ottawa scale, *ELISA* Enzyme linked immunosorbent assay, *RIA* RadioimmunoassayTable 2Participants' characteristics of included studiesAuthorADPN (Mean ± SD)BMI (Mean ± SD), kg/m2Age (Mean ± SD), yAHI (Mean ± SD)OGCGOGCGOGCGO GCGHuang et al. \[[@CR26]\]4.12 ± 2.497.74 ± 4.4226.35 ± 2.6026.02 ± 1.7851.71 ± 12.3756.37 ± 11.4939.28 ± 22.803.67 ± 1.38Zhang et al. \[[@CR8]\]4.23 ± 2.047.52 ± 2.2126.8 ± 2.525.6 ± 1.850.7 ± 12.949.6 ± 9.236.8 ± 21.42.4 ± 1.8Wolk et al. \[[@CR11]\]8.49 ± 4.696.32 ± 2.9631 ± 5.1031 ± 5.3946 ± 5.1046 ± 10.7744 ± 20.403.0 ± 2.15Sharma et al. \[[@CR15]\]4959.3 ± 3212.95706 ± 3670.829.8 ± 3.329.1 ± 2.342.3 ± 8.343.3 ± 7.832.19 ± 9.941.35 ± 0.61Ursavas et al. \[[@CR16]\]7.7 ± 5.29.1 ± 6.632.5 ± 6.731.6 ± 7.051.1 ± 8.948.4 ± 11.643.5 ± 26.72.8 ± 1.5Ebru et al.(mild) \[[@CR16]\]7.35 ± 2.714.87 ± 6.1727.6 ± 1.828.4 ± 2.4548 ± 2747 ± 39.198.0 ± 2.522.05 ± 1.32Ebru et al.(mod-sev) \[[@CR16]\]8.04 ± 6.5514.87 ± 6.1729.3 ± 4.1228.4 ± 2.4550 ± 27.1147 ± 39.1954.4 ± 66.792.05 ± 1.32Öztürk et al.(mild) \[[@CR18]\]3.5 ± 4.25.2 ± 5.232.1 ± 6.631.3 ± 5.648.8 ± 10.648.3 ± 10.89.0 ± 2.61.8 ± 1.4Öztürk et al.(mod) \[[@CR18]\]2.3 ± 1.25.2 ± 5.232.7 ± 5.831.3 ± 5.658.7 ± 8.648.3 ± 10.823.4 ± 4.61.8 ± 1.4Öztürk et al.(sev) \[[@CR18]\]2.7 ± 3.25.2 ± 5.234.0 ± 5.531.3 ± 5.650.0 ± 11.748.3 ± 10.861.6 ± 20.41.8 ± 1.4Sánchez et al. \[[@CR17]\]36.94 ± 21.4229.47 ± 15.8825.02 ± 1.2224.71 ± 2.3949.33 ± 10.7142.9 ± 9.1641.45 ± 18.32.87 ± 1.51Kritikou et al.(male) \[[@CR19]\]4.75 ± 2.414.89 ± 2.5527.09 ± 2.6026.60 ± 2.6553.87 ± 6.7652.39 ± 6.2342.42 ± 22.513.03 ± 1.98Kritikou et al.(female) \[[@CR19]\]8.96 ± 5.4811.63 ± 6.1731.52 ± 1.5430.36 ± 2.7557.28 ± 6.0054.21 ± 6.6133.94 ± 18.781.69 ± 1.61Hargens et al. \[[@CR10]\]10.0 ± 2.7713.9 ± 5.9432.4 ± 3.4631.6 ± 4.6722.8 ± 2.7722.5 ± 2.9725.4 ± 18.712.2 ± 1.27Mutairi et al.(mild) \[[@CR20]\]10.53 ± 7.4114.70 ± 13.0143.3 ± 10.540.5 ± 11.949.1 ± 17.055.8 ± 16.310.3 ± 3.82.6 ± 1.6Mutairi et al.(mod) \[[@CR20]\]10.64 ± 8.3614.70 ± 13.0149.8 ± 13.940.5 ± 11.953.0 ± 16.355.8 ± 16.318.0 ± 6.92.6 ± 1.6Mutairi et al.(sev) \[[@CR20]\]8.87 ± 7.4114.70 ± 13.0144.4 ± 16.840.5 ± 11.950.0 ± 14.855.8 ± 16.348.9 ± 13.12.6 ± 1.6Xu et al. \[[@CR28]\]7.98 ± 3.7413.43 ± 2.04----50.8 ± 11.751.3 ± 10.518.03 ± 5.102.14 ± 0.89Wen et al. \[[@CR27]\]6.13 ± 1.168.51 ± 3.8427.4 ± 5.027 ± 4.648.5 ± 10.0646 ± 10.441.3 ± 3.62.8 ± 0.4Kim et al.(mod) \[[@CR22]\]8.08 ± 1.668.90 ± 2.6324.43 ± 2.4523.88 ± 2.3038 ± 15.0426 ± 6.9114.40 ± 4.071.25 ± 1.25Kim et al.(sev) \[[@CR22]\]6.88 ± 1.788.90 ± 2.6328.69 ± 4.0523.88 ± 2.3042 ± 10.7726 ± 6.9152.71 ± 22.231.25 ± 1.25Araújo et al. \[[@CR21]\]5.38 ± 0.445.98 ± 0.8234.39 ± 0.5134.51 ± 0.6639.60 ± 1.4832.50 ± 2.0920.16 ± 3.572.55 ± 0.35Zuo et al. \[[@CR29]\]6.4 ± 3.257.24 ± 2.4227.3 ± 5.026.1 ± 1.747.3 ± 14.643.3 ± 7.820.6 ± 26.3/Lacedonia et al. \[[@CR23]\]63.43 ± 11.5380.10 ± 18.5027.29 ± 2.4127.58 ± 1.4062.80 ± 8.1958.80 ± 17.55//Yang et al. \[[@CR30]\]8.13 ± 2.2814.52 ± 4.1024.61 ± 3.8023.37 ± 3.5550.12 ± 11.2549.30 ± 10.7037.87 ± 14.90/Abdel et al. \[[@CR24]\]5.09 ± 0.475.86 ± 0.8936.00 ± 1.1036.62 ± 1.1449.92 ± 2.1047.55 ± 2.3532.17 ± 20.593.72 ± 1.69Chen et al.(mod) \[[@CR25]\]29.31 ± 11.5743.98 ± 22.1325.35 ± 2.0725.51 ± 2.1743.32 ± 11.9541.33 ± 12.4532.12 ± 10.214.86 ± 2.31Chen et al.(sev) \[[@CR25]\]25.79 ± 13.3543.98 ± 22.1326.12 ± 3.4925.51 ± 2.1742.06 ± 11.7541.33 ± 12.4572.47 ± 15.734.86 ± 2.31*ADPN* adiponectin, *BMI* body mass index, *AHI* apnea-hypopnea index

Pooled analysis {#Sec12}
---------------

The value of I^2^ was 73%, indicating that the studies were moderate heterogeneous. Therefore, the random effects model was used to combine effect size. Meta-analysis exhibited that serum/plasma adiponectin levels in OSAHS patients were significantly lower than that in controls (SMD = − 0.71, 95% CI = − 0.92 to − 0.49, *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plots of studies on adiponectin levels for OSAHS patients versus controls

Subgroup analysis {#Sec13}
-----------------

Subgroup analysis stratified by race, adiponectin source, assay approaches, average age, BMI and AHI were performed, and the results were shown in Table [3](#Tab3){ref-type="table"}. Results exhibited that adiponectin levels were significantly lower in OSAHS patients among all subgroup. In addition, we find that I^2^ would decrease when the subgroup analysis was stratified by race. Thus, race may be a potential source of heterogeneity.Table 3Subgroup analysis of adiponectin levels in osa patients and controlsSubgroupNSMD (95%CI)zpTest of heterogeneityI^2^pOverall28−0.71 (− 0.92, − 0.49)6.52\< 0.00173%\< 0.001Race White17−0.42 (− 0.64, − 0.21)3.87\< 0.00156%0.003 Nonwhite11−1.11 (−1.40, −0.82)7.48\< 0.0164%0.002Assay approaches ELISA19−0.72 (−0.94, − 0.50)6.37\< 0.00165%\< 0.001 RIA9−0.67 (−1.17, − 0.17)2.630.00984%\< 0.001Adiponectin Source Serum19−0.89 (−1.13, − 0.65)7.16\< 0.00166%\< 0.001 Plasma9−0.36 (− 0.67, − 0.04)2.200.0371%\< 0.001BMI BMI ≥ 3012−0.46 (−0.68, − 0.23)3.89\< 0.00149%0.03 BMI \< 3015−0.85 (−1.16, − 0.53)5.25\< 0.00176%\< 0.001Age Age ≥ 5013−0.85 (−1.18, − 0.53)5.15\< 0.00174%\< 0.001 Age \< 5015−0.58 (− 0.84, − 0.31)4.25\< 0.00169%\< 0.001AHI AHI ≥ 3017−0.69 (−1.00, − 0.37)4.29\< 0.00180%\< 0.001 AHI \< 3010−0.70 (− 0.97, − 0.43)5.03\< 0.00158%0.01

Sensitivity analysis {#Sec14}
--------------------

Sensitivity analysis were performed to assess the stability of the results (Fig. [3](#Fig3){ref-type="fig"}). The removal of any independent study did not significantly change the pooled results, suggesting these results were stable (data not shown). Pooled analysis using random-effect model showed that pooled SMD was − 0.71 (95% CI: -0.92, − 0.49), *P* \< 0.001). The fixed-effect model drew a similar result which pooled SMD was − 0.66 (95% CI: -0.77 to − 0.55, *P* \< 0.001).Fig. 3Sensitivity Analysis of studies on adiponectin levels for OSAHS patients versus controls

Publication Bias {#Sec15}
----------------

The funnel plot was not completely symmetrical, suggesting that the present study has some slight publication bias (Fig. [4](#Fig4){ref-type="fig"}). However, the Begg's tests (*P* = 0.06) and Egger's tests (*P* = 0.09) did not give sufficient evidence that the present study had publication bias.Fig. 4Funnel plot for all studies included in the meta-analysis

Meta-regression analysis {#Sec16}
------------------------

In meta-regression analysis, the outcome variable was the SMD of adiponectin level and the covariates included publication year, race, adiponectin source, assay approaches, average age, BMI and AHI. We can find that the adiponectin levels were significantly correlated with race (*p* = 0.002), but not significantly correlated with publication year (*P* = 0.56), adiponectin source(*P* = 0.09), assay approaches(*P* = 0.77), average age (*P* = 0.27), BMI (*P* = 0.12) and AHI (*P* = 0.28).

Discussion {#Sec17}
==========

The current meta-analysis sought to summarize all available studies on the serum/plasma adiponectin levels among OSAHS patients and control subjects. We found that patients with OSAHS had significantly lower serum/plasma adiponectin levels compared with control subjects, indicating that adiponectin may play a role in the development of OSAHS. However, previous studies have found uncertain results for the association between adiponectin levels and OSAHS. Zhang et al. \[[@CR8]\], Ebru et al. \[[@CR16]\], Ozturk et al. \[[@CR18]\] and Lacedonia et al. \[[@CR23]\] have found OSAHS to be a potential driver of decreased adiponectin levels independent of age, gender and BMI. This was similar to our results. Hypoxia induced by OSAHS has been shown to reduce adiponectin levels via disruption of mechanisms that regulate the secretion of adiponectin. Moreover, other factors such as insulin resistance and hypoxia-induced sympathetic activation may also play significant roles in reducing adiponectin levels. While Sharma et al. in a cross-sectional \[[@CR15]\] to determine whether obesity or OSAHS is responsible for adiponectin levels in patients with sleep disordered breathing, they found that no significant difference was noted in the OSAHS group compared to obese controls. Wolk et al. \[[@CR11]\] reported that higher adiponectin levels in OSAHS patients compared to controls, which suggested that OSAHS may stimulate compensatory mechanisms, which can be considered to be protective of the cardiovascular system.

Moderate heterogeneity was observed among these studies. Therefore, subgroup analysis and meta-regression analysis were performed to detect the potential source of heterogeneity. In subgroup analysis, only stratification by race I^2^ would result in a decrease of I^2^ in both white and non-white groups. In addition, meta-regression analysis also suggested that the adiponectin levels were only significantly related with race. We can speculate race may be the potential source of heterogeneity in this present meta-analysis. Therefore, the relationship between serum/plasma adiponectin levels and OSAHS from different races requires further investigation and especially the exact composition of the non-white group.

To our knowledge, this is the first meta-analysis conducted to assess the relationship between serum/plasma adiponectin levels in OSAHS patients and in control subjects. Most of clinical research studies have focused primarily on older obese males with apnea because OSAHS is more common in males and in overweight/obese populations \[[@CR31], [@CR32]\]. However, in these studies the findings were confounded by obesity, gender and age. To address these confounded factors, we firstly excluded the impact of age, gender and BMI on serum/plasma adiponectin levels in our meta-analysis. Hence, a major strength of our meta-analysis is that no statistically significant difference was found between OSAHS patients and controls in terms of age, gender and BMI. Another strength of this meta-analysis is the large sample size among patients with OSAHS. Moreover, none of the patients included had obvious coronary heart disease or chronic respiratory diseases. Performing a subgroup analysis and meta-regression analysis to better understand the effect of race, adiponectin source, assay approaches, average age, BMI and AHI on the serum/plasma adiponectin levels is also another strength of this study. However, several limitations should be acknowledged. Even though we used a broad search strategy, we cannot claim to have been exhaustive in retrieving all studies. In addition, some nonsignificant findings from existing studies remain unpublished, which may have some important information. We also found some conference abstracts that might have been included, but they lacked substantial details on some important data. A major limitation of the present study is a new bias may be introduced because of the confounding factor adjustment, which would affect the accuracy of the combined effect value. Finally, meta-analysis remains retrospective research, which is impossible to avoid the methodological deficiencies of the included studies. Therefore, the relationship between serum/plasma adiponectin levels and OSAHS needs to be verified given the limited number of studies.

In conclusion, the serum/plasma adiponectin levels were significantly lower in OSAHS patients than that in control subjects, suggesting a potential role of adiponectin in OSAHS pathogenesis, deserves further studies as a potential marker of OSAHS.

ADPN

:   Adiponectin

AHI

:   Apnea hypopnea index

BMI

:   Body mass index

CI

:   Confidence interval

ELISA

:   Enzyme linked immunosorbent assay

IR

:   Insulin resistance

NOS

:   Newcastle-Ottawa scale

OSAHS

:   Obstructive sleep apnea hypopnea syndrome

RIA

:   Radioimmunoassay

SMD

:   Standard mean difference

We thank the dedicated researchers who contributed the explore data for us.

Funding {#FPar1}
=======

This work was supported by the International Science & Technology Cooperation Program of China (2015DFA30160) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201605).

Availability of data and materials {#FPar2}
==================================

Please contact author for data requests.

Conception and design: Mi Lu, Zhenjia Wang and Fang Fang. Provision of study materials: Mi Lu, Peng Wei and Fang Fang. Collection and assembly of data: Mi Lu, Zhenjia Wang and Chunhua Hu. Data analysis and interpretation: Mi Lu, Yongxiang Wei and Fang Fang. Manuscript writing: Mi Lu and Fang Fang. Revised the language/article: Fang Fang, John Elsby Sanderson and Mi Lu. Final approval of manuscript: All authors.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
